Talquetamab in Elderly Patients
A Phase 2 Single-Arm Study of Subcutaneous Talquetamab in Elderly Patients With Multiple Myeloma in Early Relapse
More Information
- Trial Status
- Accepting patients
- Trial Phase
- Phase 2
- Enrollment
- 23 patients (estimated)
- Sponsors
- Icahn School of Medicine at Mount Sinai
- Collaborators
- Johnson & Johnson
- Tags
- Bispecific Antibody, GPRC5D, CD3
- Trial Type
- Treatment
- Last Update
- SparkCures ID
- 2061
- NCT Identifier
- NCT06827860
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print this trial to share with your doctor.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.